Nephron’s MedTech Data Insights – Recovery Scorecard

Today, we’re highlighting a great example of how Chris Pasquale’s uniquely data-driven MedTech franchise is adding value to subscribers’ investment process.   In addition to COVID ebbs and flows globally, a host of new macro headwinds have entered the fray in recent months, complicating the picture even more for MedTech investors. To gauge how these variables are impacting procedure volumes in the areas that matter most to the sector, Nephron’s Med Tech – Recovery Scorecard analyzes purchasing data from ~25% of U.S. hospitals (as well as a large number of ASCs) and compares average sales per selling day for each month to a pre-COVID baseline across 28 different product categories.  For more information on  accessing Nephron’s MedTech product, email